Potocki–Shaffer syndrome

Potocki–Shaffer syndrome, abbreviated PSS, is an ultra-rare contiguous gene deletion syndrome caused by loss of the proximal short arm of chromosome 11 at band 11p11.2, classically presenting with multiple osteochondromas, parietal foramina and craniofacial dysostosis.

Intellectual disability, hypotonia and seizures are part of the phenotype because the deleted interval contains PHF21A in addition to the bone genes ALX4 and EXT2, and fewer than 100 patients have been reported worldwide.

Terminology and classification

• The eponym Potocki–Shaffer syndrome honours the two clinical geneticists who described the deletion phenotype in 1996, and the abbreviation PSS is standard in the subsequent literature.
• Descriptive synonyms are proximal 11p deletion syndrome and DEFECT11 syndrome, and older cytogenetic reports simply called it an interstitial deletion of 11p11.2-p12.
• ICD-10 classifies the deletion in Q93.5, deletion of other part of chromosome 11, a residual category that also contains deletions with different breakpoints and different phenotypes.
• ICD-11 release 2025-01 assigns LD44.B1, and the code should be quoted with the release because WHO updates the chromosomal deletion block on a rolling cycle.
• Interoperability identifiers are MONDO:0011022, Orphanet ORPHA:52022, OMIM 601224, UMLS C1832588, MeSH C538356, GARD 9762, SNOMED CT 702346005 and Wikidata Q7234989.
• Orphanet enters it as a rare developmental defect during embryogenesis with a prevalence class below 1 per 1,000,000, and it belongs to the contiguous gene deletion syndromes rather than to the single-gene skeletal dysplasias.

History

• Potocki and Shaffer described the interstitial 11p11.2-p12 deletion in 1996 and recognised that the combination of exostoses and parietal foramina defined a new contiguous gene syndrome.
• The individual genes were mapped over the following decade: EXT2 was established as the exostosis gene at 11p11.2, and ALX4 was linked to parietal foramina in 2000 by Wuyts and colleagues.
• PHF21A was later identified as the gene responsible for the intellectual disability, hypotonia, seizures and craniofacial features, which explained why the phenotype is broader than a pure bone disorder.
• Swarr and colleagues published clinical and molecular data in 2010 that clarified the minimum deleted region and gave the first practical management recommendations for affected children.
• The 2010 ACMG consensus on chromosomal microarray as a first-tier test for developmental delay, followed by the 2021 ACMG technical standards, made detection of 11p11.2 deletions routine rather than exceptional.
• Trajkova and colleagues published a systematic review in 2020 that collected the reported cases and refined the genotype-phenotype map of the deletion.

Epidemiology

• Orphanet assigns a prevalence class below 1 per 1,000,000, and the published literature contains fewer than 100 patients, which makes PSS one of the rarest contiguous gene syndromes.
• No population screening study exists, so all frequency statements derive from case reports and small cohorts ascertained through developmental delay or skeletal surveys.
• Both sexes are affected in the reported cases, and no ethnic or geographic clustering has been observed, consistent with de novo deletion as the usual mechanism.
• Most deletions are de novo, but inheritance from an affected parent is possible because the syndrome is compatible with reproduction in mildly affected individuals.
• The minimum critical region is about 2.1 megabases, and larger deletions extending toward 11p12 add genes and increase the likelihood of intellectual disability and seizures.
• Multiple osteochondromas are the most consistent skeletal finding, and parietal foramina with craniofacial dysostosis are present in the majority of reported patients.
• Intellectual disability is reported in a substantial minority and is more frequent with deletions that include PHF21A, whereas isolated EXT2 loss gives exostoses without cognitive impairment.
• Named sources are Orphanet ORPHA:52022, which supplies the European prevalence class, and GARD 9762, which maintains a North American patient-facing summary updated from the published cases.

Pathophysiology

• The syndrome results from heterozygous deletion of 11p11.2, and the phenotype is explained by haploinsufficiency of several contiguous genes rather than by a single dominant mutation.
• ALX4 encodes a paired-like homeodomain transcription factor required for parietal bone ossification, and its loss leaves persistent parietal foramina that may close partially with age.
• EXT2 encodes a glycosyltransferase in the heparan sulphate biosynthetic pathway and acts as a tumour suppressor in cartilage, so haploinsufficiency permits multiple osteochondromas at the growth plates of long bones.
• PHF21A encodes a plant homeodomain protein involved in chromatin-mediated transcriptional repression, and its loss disrupts neuronal gene regulation and produces hypotonia, developmental delay and seizures.
• The deletion is generated by non-allelic homologous recombination or by replication-based mechanisms at the 11p11.2 breakpoints, and the resulting copy-number loss is detectable only by microarray or targeted dosage methods.
• Osteochondromas are cartilage-capped bony outgrowths that continue to grow while the physis remains open, which is why they enlarge during childhood and stop after skeletal maturity.

Clinical features

• Multiple osteochondromas arise from the metaphyses of long bones, ribs, scapulae and pelvis, are often palpable as hard painless lumps, and may cause deformity, limb length discrepancy or mechanical irritation of tendons and nerves.
• Parietal foramina are large persistent openings in the parietal bones that are palpable as soft spots in infancy and are best shown on skull radiographs or computed tomography.
• Craniofacial dysostosis includes frontal bossing, widely spaced eyes, a short nose, midface hypoplasia and sometimes a cleft palate or conductive hearing loss.
• Neurodevelopmental features include hypotonia in infancy, global developmental delay, mild to moderate intellectual disability, speech delay and seizures in a minority of patients.
• Named complications are pathological fracture through an osteochondroma, malignant transformation to chondrosarcoma, compressive neuropathy, raised intracranial pressure from large skull defects and seizure-related injury.
• Short stature and feeding difficulties are common in childhood, and adults may have residual limb deformity or chronic pain from previous exostoses.

Diagnosis

• Diagnosis rests on detection of the 11p11.2 deletion by chromosomal microarray, which is the first-tier test for developmental delay and also defines the deletion size and gene content.
• Multiplex ligation-dependent probe amplification or fluorescence in situ hybridisation can confirm the deletion when microarray is unavailable, and a normal karyotype does not exclude it.
• Radiographic skeletal survey documents the number and distribution of osteochondromas, and skull radiographs show parietal foramina and delayed ossification of the parietal bones.
• Magnetic resonance imaging of a painful or rapidly enlarging osteochondroma is used to measure the cartilage cap, because a cap thicker than 2 centimetres after skeletal maturity raises concern for chondrosarcoma.
• The differential diagnosis includes hereditary multiple osteochondromas from EXT1 or EXT2 point variants, isolated parietal foramina from ALX4 variants, WAGR syndrome from an 11p13 deletion and 22q11.2 deletion syndrome.
• Baseline evaluation comprises developmental and audiological assessment, echocardiography when a cardiac anomaly is suspected, and parental testing to establish whether the deletion is inherited.

Management

• Management is multidisciplinary and directed at the skeletal, neurodevelopmental and craniofacial consequences, because no treatment reverses the deletion.
• Symptomatic osteochondromas are excised when they cause pain, deformity, growth disturbance or neurovascular compression, and surgery is usually deferred until skeletal maturity to reduce recurrence.
• Surveillance for malignant transformation consists of clinical review for new pain or rapid growth after skeletal maturity and magnetic resonance imaging of any suspicious lesion, following the 2021 ESMO–EURACAN bone sarcoma guideline.
• Large parietal foramina in infancy require handling advice and helmet protection until they close, and persistent defects with cosmetic or pressure concerns can be repaired by cranioplasty.
• Seizures are treated with standard antiseizure medication such as levetiracetam or valproate, chosen according to seizure type and avoiding valproate in girls of childbearing potential.
• Developmental therapies, speech therapy and educational support address the intellectual and language deficits, and behavioural problems may require psychological input or risperidone in selected cases.
• Orthopaedic follow-up should monitor limb length, spinal curvature and joint function through growth, and hearing should be reassessed because conductive loss can worsen language outcomes.
• Prognosis is dominated by the skeletal and neurological burden rather than by mortality, and most patients survive to adulthood with residual deformity and learning difficulties.
• Genetic counselling explains the 50 per cent recurrence risk for an affected parent and the low risk of gonadal mosaicism after a de novo deletion, and prenatal microarray is available for subsequent pregnancies.

Research and controversies

• Whether PHF21A loss alone explains the intellectual disability or whether other genes in the interval contribute is unresolved, and patients with atypical deletions are the key to separating the contributions.
• The true prevalence is unknown because mildly affected adults with exostoses only are never tested, and newborn screening does not include this deletion.
• There is no consensus on the surveillance interval for osteochondroma malignant transformation in PSS, and recommendations are extrapolated from hereditary multiple osteochondromas.
• Growth hormone therapy has been used anecdotally for short stature, but no trial has tested it and the growth failure is not clearly hormone-dependent.
• Patient numbers are too small for randomised trials, so international registries and deep phenotyping are the stated priorities for defining adult outcome and reproductive risk.